Novel Mechanism of Action: PRAX-562 targets T-type calcium channels, offering a differentiated approach for Essential Tremor compared to existing therapies and potentially leading to better efficacy and tolerability.

FDA Breakthrough Therapy Designation: The lead program, PRAX-562 for Essential Tremor, has received this designation, which can expedite development and regulatory review, potentially accelerating market entry.

Addressing Large Unmet Needs: Praxis focuses on CNS disorders like Essential Tremor and Focal Epilepsy, areas with significant patient populations and a lack of sufficiently effective or well-tolerated treatments.